COMPANY

Expression Therapeutics, LLC

HQ: Tucker, GA source · expressiontherapeutics.com ↗ · Southeast

Keywords: cell therapy oncology hematology factor VIII deficiency neuroendocrine tumors gene therapy Hemophilia A neuroblastoma

Location: Tucker, GA · source · Oct 15, 2026

Profile checked Oct 10, 2026

1Trials (company is sponsor)19NIH grants

Funding and NIH signals

NIH award NIH awarded $1.13M (SBIR Phase II 2R44CA281633-02A1, competing renewal, notice Sep 17, 2026). NIH RePORTER 2R44CA281633-02A1 (Sep 17, 2026)
Evidence (1 event)
- Sep 17, 2026 · NIH RePORTER 2R44CA281633-02A1
  Organization: EXPRESSION THERAPEUTICS; City/State: TUCKER, GA; Project number: 2R44CA281633-02A1; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 1131730; Administering IC: National Cancer Institute; Project title: ADEPT-STAR therapy for high risk neuroblastoma; Organization type: Domestic For-Profits

Job counts as of Oct 18, 2026. All funding and NIH signals

Timeline

Sep 17, 2026 Grant Government grant — SBIR: $1.13M (annual award, as published), announced Sep 17, 2026. Agency: NIH/NCI. Source: government award database. source ↗
Dec 4, 2024 Grant Government grant — SBIR: $400,000 (annual award, as published), announced Dec 4, 2024. Agency: NIH/NCI. Source: government award database. source ↗
Sep 1, 2024 Trial start Phase 1: Hematopoietic Stem Cell Transplantation Gene Therapy for Treatment of Severe Hemophilia A source ↗

Upcoming milestones

2029-08 (ESTIMATED) · Phase 1 · Hematopoietic Stem Cell Transplantation Gene Therapy for Treatment of Severe Hemophilia A · NCT04418414

Estimated primary completion per ClinicalTrials.gov. Dates move.

Funding

Last 2 years.

Sep 17, 2026 Government grant — SBIR: $1.13M (annual award, as published), announced Sep 17, 2026. Agency: NIH/NCI. Source: government award database. source ↗
Dec 4, 2024 Government grant — SBIR: $400,000 (annual award, as published), announced Dec 4, 2024. Agency: NIH/NCI. Source: government award database. source ↗

Clinical trials (lead sponsor) 1

Record	Title	Phase	Status	Start	Primary completion
NCT04418414	Hematopoietic Stem Cell Transplantation Gene Therapy for Treatment of Severe Hemophilia A	Phase 1	Not yet recruiting	Sep 1, 2024	2029-08 (estimated)

NIH awards 19

Annual award amounts. Total $9.4M.

Sep 19, 2023 NIH award 1R43CA281633-01A1 FY2023: $400,000 awarded for that fiscal year; activity R43 (SBIR); PI PETRICH, BRIAN G; recipient as written: EXPRESSION THERAPEUTICS, TUCKER, GA. ADEPT-STAR therapy for high risk neurobl source ↗
Aug 11, 2019 NIH award 5R44HL110448-03 FY2019: $752,051 awarded for that fiscal year; activity R44 (SBIR); PI BOUT DENNING, GABRIELA; recipient as written: EXPRESSION THERAPEUTICS, TUCKER, GA. Clinical Testing of the First Suspen source ↗
Apr 18, 2019 NIH award 1R43HL146045-01 FY2019: $224,999 awarded for that fiscal year; activity R43 (SBIR); PI BOUT DENNING, GABRIELA; recipient as written: EXPRESSION THERAPEUTICS, TUCKER, GA. A Microscale Platform for Augmentati source ↗
Aug 8, 2018 NIH award 2R44HL110448-02A1 FY2018: $747,641 awarded for that fiscal year; activity R44 (SBIR); PI BOUT DENNING, GABRIELA; recipient as written: EXPRESSION THERAPEUTICS, TUCKER, GA. Clinical Testing of the First Susp source ↗
Jan 24, 2017 NIH award 1R43HL135969-01 FY2017: $224,976 awarded for that fiscal year; activity R43 (SBIR); PI BOUT DENNING, GABRIELA; recipient as written: EXPRESSION THERAPEUTICS, TUCKER, GA. Preclinical Evaluation of Ancestral source ↗
Aug 3, 2016 NIH award 1R43HL132725-01 FY2016: $224,223 awarded for that fiscal year; activity R43 (SBIR); PI BOUT DENNING, GABRIELA; recipient as written: EXPRESSION THERAPEUTICS, TUCKER, GA. Selection and preclinical validation source ↗
May 4, 2015 NIH award 5R44HL114241-03 FY2015: $826,775 awarded for that fiscal year; activity R44 (SBIR); PI BOUT DENNING, GABRIELA; recipient as written: EXPRESSION THERAPEUTICS, TUCKER, GA. Bioengineered factor VIII gene thera source ↗
Jan 9, 2015 NIH award 5R44HL117511-03 FY2015: $673,613 awarded for that fiscal year; activity R44 (SBIR); PI BOUT DENNING, GABRIELA; recipient as written: EXPRESSION THERAPEUTICS, TUCKER, GA. Bioengineered Recombinant FVIII source ↗
Apr 23, 2014 NIH award 2R44HL114241-02A1 FY2014: $659,086 awarded for that fiscal year; activity R44 (SBIR); PI BOUT DENNING, GABRIELA; recipient as written: EXPRESSION THERAPEUTICS, TUCKER, GA. Bioengineered factor VIII gene the source ↗
Jan 31, 2014 NIH award 2R44HL117511-02 FY2014: $809,918 awarded for that fiscal year; activity R44 (SBIR); PI BOUT DENNING, GABRIELA; recipient as written: EXPRESSION THERAPEUTICS, TUCKER, GA. Bioengineered Recombinant FVIII source ↗
Jan 23, 2013 NIH award 1R43HL117511-01 FY2013: $386,432 awarded for that fiscal year; activity R43 (SBIR); PI BOUT DENNING, GABRIELA; recipient as written: EXPRESSION THERAPEUTICS, TUCKER, GA. Manufacturing Process Development fo source ↗
Aug 1, 2012 NIH award 1R43HL110448-01A1 FY2012: $296,320 awarded for that fiscal year; activity R43 (SBIR); PI BOUT DENNING, GABRIELA; recipient as written: EXPRESSION THERAPEUTICS, TUCKER, GA. Development of a novel production source ↗
Jun 14, 2012 NIH award 1R43HL114241-01 FY2012: $378,456 awarded for that fiscal year; activity R43 (SBIR); PI BOUT DENNING, GABRIELA; recipient as written: EXPRESSION THERAPEUTICS, TUCKER, GA. Bioengineered factor VIII gene thera source ↗
Jun 30, 2011 NIH award 5R42HL090112-03 FY2011: $885,011 awarded for that fiscal year; activity R42 (STTR); PI DOERING, CHRISTOPHER BRADLEY; recipient as written: EXPRESSION THERAPEUTICS, TUCKER, GA. High Expression Recombinant Fa source ↗
Jun 16, 2010 NIH award 2R42HL090112-02A1 FY2010: $575,118 awarded for that fiscal year; activity R42 (STTR); PI DOERING, CHRISTOPHER BRADLEY; recipient as written: EXPRESSION THERAPEUTICS, TUCKER, GA. High Expression Recombinant source ↗
Jan 28, 2010 NIH award 5R42HL083531-03 FY2010: $420,475 awarded for that fiscal year; activity R42 (STTR); PI DOERING, CHRISTOPHER BRADLEY; recipient as written: EXPRESSION THERAPEUTICS, TUCKER, GA. Ex Vivo Gene Therapy for Hemop source ↗
Jan 30, 2009 NIH award 2R42HL083531-02 FY2009: $706,219 awarded for that fiscal year; activity R42 (STTR); PI DOERING, CHRISTOPHER BRADLEY; recipient as written: EXPRESSION THERAPEUTICS, TUCKER, GA. Ex Vivo Gene Therapy for Hemop source ↗
Apr 7, 2008 NIH award 1R41HL090112-01A2 FY2008: $100,000 awarded for that fiscal year; activity R41 (STTR); PI DOERING, CHRISTOPHER BRADLEY; recipient as written: EXPRESSION THERAPEUTICS, TUCKER, GA. High Expression Recombinant source ↗
Aug 23, 2006 NIH award 1R41HL083531-01A1 FY2006: $100,000 awarded for that fiscal year; activity R41 (STTR); PI DOERING, CHRISTOPHER BRADLEY; recipient as written: EXPRESSION THERAPEUTICS, Tucker, GA. Ex Vivo Gene Therapy of Hemo source ↗